Summary
Abbott Laboratories reported solid performance in its fiscal year ending December 31, 2025, with total net sales increasing by 5.7% to $44.3 billion. This growth was primarily driven by the Medical Devices segment, which saw a 12.6% increase in net sales, and the Established Pharmaceutical Products segment, with a 6.6% increase. The company continues to invest in innovation across its segments, with notable product approvals in Medical Devices including the Volt™ Pulsed Field Ablation System and the Tendyne™ transcatheter mitral valve replacement system. A significant strategic development for Abbott is the definitive agreement to acquire Exact Sciences Corporation for approximately $21 billion, expected to significantly expand Abbott's presence in the cancer diagnostics market. While the company faced headwinds in its Diagnostic Products segment due to declining COVID-19 testing sales and market conditions in China, and a slight decrease in Nutritional Products sales volume in the U.S., overall financial results indicate a positive trajectory supported by strong performance in its core Medical Devices and Pharmaceuticals businesses. Abbott also continued its commitment to shareholders through a 7.1% increase in dividends declared in 2025.
Financial Highlights
51 data points| Revenue | $44.33B |
| Cost of Revenue | $19.32B |
| Gross Profit | $25.01B |
| R&D Expenses | $2.94B |
| SG&A Expenses | $12.33B |
| Operating Expenses | $36.27B |
| Operating Income | $8.05B |
| Net Income | $6.52B |
| EPS (Basic) | $3.73 |
| EPS (Diluted) | $3.72 |
| Shares Outstanding (Basic) | 1.74B |
| Shares Outstanding (Diluted) | 1.75B |
Key Highlights
- 1Total net sales increased by 5.7% to $44.3 billion, driven by strong performance in Medical Devices and Established Pharmaceuticals.
- 2Announced definitive agreement to acquire Exact Sciences Corporation for approximately $21 billion to enter the cancer diagnostics market.
- 3Medical Devices segment sales grew 12.6%, with significant contributions from Diabetes Care (CGM systems up 17.4%), Heart Failure, Electrophysiology, and Structural Heart.
- 4Established Pharmaceutical Products segment sales increased 6.6%, with strong growth in emerging markets across multiple therapeutic areas.
- 5Diagnostic Products segment sales decreased 4.3%, primarily due to the decline in COVID-19 testing-related sales and challenges in the Chinese market.
- 6Nutritional Products segment sales saw a modest increase of 0.4%, with growth in adult nutritionals and international pediatric nutritionals offset by lower U.S. pediatric volumes.
- 7Abbott increased its quarterly dividend by 7.1% in 2025, demonstrating a commitment to returning capital to shareholders.